Hyperion Therapeutics Receives FDA Fast Track Designation For Glycerol Phenylbutyrate For The Treatment Of Urea Cycle Disorders

Links shared publicly online about this topic.

  • 788
    total visits

Hyperion Therapeutics Receives FDA Fast Track Designation For Glycerol Phenylbutyrate For The Treatment Of Urea Cycle Disorders

medicalnewstoday.com —

Hyperion Therapeutics, Inc. announced that its investigational compound glycerol phenylbutyrate (HPN-100) has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) as

View full resource at medicalnewstoday.com

Tags: Disease and Condition, Drug, FDA

  • Share

Most Recently Shared on October 20, 2010 at 7:05 pm By:

mnt_genetics MNT Genetics News

Hyperion Therapeutics Receives FDA Fast Track Designation For Glycerol Phenylbutyrate For The Treatment Of Urea Cycle ... http://mnt.to/3LsL

2 years ago...

Reply

Retweet

Favorite

Also Shared By:

MNT Urology MNT Urology

MNT Blood MNT Blood

MNT Drug Approvals MNT Drug Approvals

Advertisement